Do patients with cN0 oral squamous cell carcinoma benefit from elective neck dissection? A large-scale population-based study

医学 颈淋巴结清扫术 比例危险模型 口腔颌面外科 内科学 危险系数 肿瘤科 基底细胞 生存分析 子群分析 外科 置信区间
作者
Qiuyu Wu,Yuanhang Xia,Ling Qiu,Shuqiong Wen,Qunxing Li,Gao Xiang,Wen-Rong Jiang,Tao Wang,Ping Ji,Zhanpeng Ou
出处
期刊:BMC Oral Health [Springer Nature]
卷期号:24 (1)
标识
DOI:10.1186/s12903-023-03632-5
摘要

Abstract Background The neck management of clinical-nodal negative (cN0) oral squamous cell carcinoma (OSCC) remains controversial. Elective neck dissection (END) and observation are the main strategies, but it is still not clear who could benefit the most from END. The purpose of this study was to clarify the potential clinical factors that affect the therapeutic value of END and to explore the actual characteristics associated with benefit from END. Methods Patients with cN0 OSCC were identified in the SEER database from 2000 to 2019. 5-year Overall survival (OS) and disease-specific survival (DSS) were analyzed using the Kaplan‒Meier method, and the hazard ratios (HRs) for survival were estimated using the Cox regression model. Multiple subgroup analyses of DSS and OS among different factors, comparing END and No END, were performed. Results A total of 17,019 patients with cN0 OSCC were included. The basic survival analysis and Cox regression model showed that END increased the probability of 5-year DSS and OS and was an independent prognostic factor. However, among patients who underwent only primary tumor surgery, no significant differences were found between the END and No END groups in 5-year DSS ( P = 0. 585) and OS ( P = 0.465). Further subgroup analysis showed that primary sites and T stage, but not other factors, might influence the benefit of END. Significant differences were found for T1 ( P < 0.001 for OS) and T2 ( P = 0.001 for DSS and < 0.001 for OS) tongue squamous cell carcinoma (TSCC) but not for other primary tumor sites. Conclusion This large-scale retrospective population-based cohort study suggests that not all patients with cN0 OSCC could benefit from END. Patients with cN0 TSCC are recommended to undergo END, especially with early-stage tumors.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LI完成签到,获得积分10
2秒前
pluto应助狂野沧海采纳,获得10
2秒前
921完成签到,获得积分10
3秒前
xxx完成签到,获得积分10
3秒前
蓝天发布了新的文献求助10
3秒前
4秒前
4秒前
dai完成签到,获得积分10
5秒前
乐乐应助水123采纳,获得10
7秒前
7秒前
Snoopy发布了新的文献求助50
7秒前
CipherSage应助ziyue采纳,获得10
8秒前
WEI发布了新的文献求助10
9秒前
研友_VZG7GZ应助nikola采纳,获得10
9秒前
小池完成签到,获得积分10
11秒前
11秒前
MMI完成签到 ,获得积分10
12秒前
矢思然完成签到,获得积分10
13秒前
dw发布了新的文献求助10
13秒前
Jim完成签到,获得积分10
16秒前
mahaha发布了新的文献求助10
17秒前
Aaron完成签到 ,获得积分10
17秒前
扁扁xx完成签到 ,获得积分10
20秒前
薏仁完成签到 ,获得积分10
20秒前
JJJ发布了新的文献求助10
20秒前
慕青应助He采纳,获得10
20秒前
李健应助哆来米采纳,获得10
21秒前
杨云完成签到 ,获得积分10
22秒前
22秒前
量子星尘发布了新的文献求助10
22秒前
学术钟意完成签到,获得积分10
23秒前
24秒前
曹操的曹发布了新的文献求助10
24秒前
5年科研3年毕业完成签到,获得积分10
25秒前
鈮宝完成签到 ,获得积分10
25秒前
27秒前
水123发布了新的文献求助10
27秒前
27秒前
mahaha完成签到,获得积分10
29秒前
核桃发布了新的文献求助10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Clinical Microbiology Procedures Handbook, Multi-Volume, 5th Edition 临床微生物学程序手册,多卷,第5版 2000
人脑智能与人工智能 1000
King Tyrant 720
Silicon in Organic, Organometallic, and Polymer Chemistry 500
Peptide Synthesis_Methods and Protocols 400
Principles of Plasma Discharges and Materials Processing, 3rd Edition 400
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5603942
求助须知:如何正确求助?哪些是违规求助? 4688789
关于积分的说明 14856201
捐赠科研通 4695596
什么是DOI,文献DOI怎么找? 2541056
邀请新用户注册赠送积分活动 1507200
关于科研通互助平台的介绍 1471832